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A B S T R A C T
Purpose
Advanced prostate cancer (PC) is associated with substantial psychosocial morbidity. We sought to
determine whether mindfulness-based cognitive therapy (MBCT) reduces distress in men with
advanced PC.
Methods
Men with advanced PC (proven metastatic and/or castration-resistant biochemical progression) were
randomly assigned to an 8-week, group-based MBCT intervention delivered by telephone (n = 94)
or to minimally enhanced usual care (n = 95). Primary intervention outcomes were psychological
distress, cancer-speciﬁc distress, and prostate-speciﬁc antigen anxiety. Mindfulness skills were
assessed as potential mediators of effect. Participants were assessed at baseline and were
followed up at 3, 6, and 9months. Main statistical analyses were conducted on the basis of intention
to treat.
Results
Fourteen MBCT groups were conducted in the intervention arm. Facilitator adherence ratings were
high (. 93%). Using random-effectsmixed-regressionmodels, intention-to-treat analyses indicated no
signiﬁcant changes in intervention outcomes or in engagement with mindfulness for men in MBCT
compared with those receiving minimally enhanced usual care. Per-protocol analyses also found no
differences between arms in outcomes or engagement, with the exception of the mindfulness skill of
observing, which increased over time for men in MBCT compared with usual care (P = .032).
Conclusion
MBCT in this format was not more effective thanminimally enhanced usual care in reducing distress
in men with advanced PC. Future intervention research for these men should consider approaches
that map more closely to masculinity.
J Clin Oncol 35:291-297. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Prostate cancer (PC) is the second most common
cancer diagnosed in men worldwide,1 with global
estimates of . 3.8 million survivors living with
PC within 5 years of diagnosis.1a Although most
men in developed countries are diagnosed with
localized cancers, 40% of these men might expect
their cancer to progress, and up to 20% will
become castration resistant or metastatic.2 Men
with castration-resistant PC face a future of in-
curable disease, with the disease and treatment
severely affecting quality of life. Androgen dep-
rivation is associated with increased risks of
skeletal events, sarcopenia, cardiovascular disease,
hot ﬂushes, reduced energy, sexual dysfunction,
and obesity.3 Psychosocial morbidities include de-
pression, anxiety, and post-traumatic stress disor-
der,4 and the risk of suicide is increased.5
Mindfulness-based approaches have been pro-
posed as an effective way forward to combat the
psychological distress associated with cancer.6,7
Mindfulness involves open awareness of current
experience and the intention to observe habits of
reacting as they arise, leading the person to be-
come less reactive to difﬁcult experiences and to
approach equanimity regarding the illness expe-
rience, including related negative emotions and
thoughts. Both mindfulness-based stress reduc-
tion and mindfulness-based cognitive therapy
(MBCT) seem to be helpful for people with
cancer.6 MBCT differs from mindfulness-based
stress reduction in that it has a more explicit
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focus on cognition and the relationship between thinking and
mood. This is particularly relevant for people coping with stressful
life events such as cancer, in whom rumination about the causes
and meaning of the illness may contribute to distress. To date,
mindfulness intervention studies in cancer have focused on pa-
tients with breast cancer and have been limited by a lack of clarity
in protocol design, nonadherence to CONSORT recommenda-
tions, and biased sampling.8-13 Consequently, the extent to which
mindfulness may be effective in ameliorating the psychosocial
distress experienced by men with PC is unknown, and despite the
escalating popularity of this approach across multiple contexts,14
more high-quality research is needed to clearly establish its efﬁcacy
in cancer populations and to guide practice.
Despite the high psychosocial morbidity experienced by men
with advanced PC, there has been scant intervention research to
improve outcomes for these patients.15 Group-based psychosocial
interventions are acceptable to men with advancing disease and
may improve mental well-being; however, research is preliminary.
One study found a group-based, multidisciplinary, quality-of-life
intervention to be acceptable to men with biochemical recurrence,
with improvements in mental well-being, compared with a wait list
control group.16 AWeb-delivered, group, cognitive-behavioral, stress
management program for racially diverse men with advanced PC
found reductions in depressive symptoms compared with men who
received attention control.17 Finally, a study group ofMBCT formen
with advanced PC reported improvements in anxiety over time.18
However, these studies were small and were not designed to test
effectiveness. Hence, how to improve psychosocial outcomes for
these men remains unclear.
We undertook a randomized controlled trial to assess the
effectiveness of MBCT in reducing psychological distress in men
with advanced PC. MBCT delivered by group teleconference over
eight weekly sessions was compared with minimally enhanced
usual care, with participants assessed prospectively over a 9-month
period. We hypothesized that, relative to men who received mini-
mally enhanced usual care, men who received MBCT would have
higher engagement with mindfulness and consequent lower psy-
chological and cancer-speciﬁc distress. Quality of life and beneﬁt
ﬁnding were assessed as secondary outcomes.
METHODS
Study Design
A two-arm randomized controlled trial was conducted in Aus-
tralia. Ethical approval was obtained from the human research ethics
committees of Grifﬁth University (PSY/15/12/HREC), the Prince
Charles Hospital (HREC/12/QPCH/101), and other hospitals across
Australia when necessary.19 The study was guided by the CONSORT
statement.
Participants
Eligible participants were men with advanced PC (proven metastatic
or castration-resistant biochemical progression) who were able to read and
speak English; had no history of head injury, dementia, or psychiatric
illness; had no concurrent cancer; and had telephone access. Most were
referred to the study by their clinician, and others self-referred through PC
support groups and media promotion. Referring sites were treatment
centers across Australia and clinicians from the Australian and New
Zealand Urogenital and Prostate Cancer Trials Group. Participants
provided written informed consent.
Random Assignment
After recruitment and baseline assessment, using an electronic
database, participants were randomly allocated to MBCT or to a mini-
mally enhanced usual care (control) group. A random assignment se-
quence was undertaken by the project manager and was concealed from
the investigators. Random assignment occurred in blocks of 14, with
each condition randomly generated seven times within each block. This
ensured an unpredictable allocation sequence with equal numbers of
men in each condition at the completion of each block and allowed for
sufﬁcient men to form groups (of seven) in the MBCT condition.
Random assignment occurred within two larger state-based groupings
to manage the formation of the MBCT groups within different state
time zones.
Procedures
Assessments were conducted before the intervention and at 3-, 6-,
and 9-month follow-up. Sociodemographic data were collected via tele-
phone interviews and clinical data through medical record review. Out-
come data were collected via self-administered questionnaires at each
assessment point.
Participants assigned to MBCT were enrolled in one of the tele-
conference groups by the project manager. MBCT followed the manual of
Segal et al20, for cancer-speciﬁc MBCT21 with novel components for men
with advanced PC18 and telephone delivery. Previous research has dem-
onstrated that MBCT and other mindfulness-based approaches delivered
through teleconferencing methods are both feasible and effective.22,23 In
this study, a tele-based approach was a feasible method of delivery to
include patients who lived in rural/remote regions of the country or who
were too unwell to travel to participate. Another beneﬁt was that this
approach would allow immediate research translation into community-
based settings should the intervention prove effective.
The program included eight group sessions delivered at weekly in-
tervals. Each participant had an individual introductory telephone call with
their facilitator to allow them to connect, prepare for the program, and
enhance motivation. Participants unable to attend one or more sessions
were offered a shortened, one-on-one, catch-up session with the facilitator
to help rejoin the group at the next session. Each session was designed to
run for 1.25 hours, with short meditations (15 minutes or less) to support
group engagement and to alleviate practical concerns (eg, holding the
telephone receiver). Workbooks included session plans so that participants
could navigate telephone sessions more easily and interactive worksheets
to keep group discussions on task. Peer interaction was directed at support
for the learning of mindfulness skills and mutual support in facing the
challenges of advanced PC.
Other strategies were implemented to support treatment ﬁdelity.24
Sessions were facilitated by health professionals with experience in
oncology and professional training in MBCT. Facilitators received
additional training in the study-speciﬁc protocol and were supervised
weekly by study investigators with extensive clinical expertise in MBCT
delivery. Delivery was tailored to the teleconference context by training
facilitators to use explicit communication, such as encouraging group
members to say their name before contributing, listening closely to the
tone of participants’ voices, giving extra time for responses, and having
explicit rules for how the group would interact. To support adherence,
facilitators completed a checklist of components to be delivered at each
session, and treatment was manualized. Teleconference sessions were
audiotaped, with 15% reviewed to assess adherence. A coding scheme
measured the extent to which each session component was imple-
mented by the facilitator. Two trained coders independently rated
each session to allow assessment of interrater agreement. Coder dis-
agreement was resolved via supervised discussion to generate a ﬁnal set
of codes.
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Participants were given self-help materials including Full Catas-
trophe Living,25 an audio-recorded meditation, and the other resources
provided in the usual care group. Daily home practice of mindfulness
meditation was strongly encouraged, with participants asked to engage
in one of the four 35-minute practices (body scan, moving meditation,
mixed mindfulness meditation, silent practice with bells at 5-minute
intervals), depending on the stage of the course. Moving meditation
consisted of gentle mindful movements and stretches, mixed mind-
fulness included mindfulness of different aspects of current experience,
and silent practice covered self-guided meditation. A daily home
practice diary was provided. At the end of the program, participants
completed items about its helpfulness and their continued practice of
mindfulness meditation.
The control condition was usual care (standard medical manage-
ment) minimally enhanced with patient education that included existing
evidence-based patient education materials: a consumer guide to advanced
PC, relaxation information and a guided audio relaxation CD, coping-
with-cancer booklets, a guide on nutrition for people with cancer, and
information about free telephone-based cancer information and support
services in the participant’s home state.
Outcome
Primary outcome measures were the Brief Symptom Inventory-18,26
the Impact of Event Scale,27 and the Prostate-Speciﬁc Antigen Anxiety
subscale of the Memorial Anxiety Scale for Prostate Cancer.28 Higher
scores on the ﬁrst two measures indicated greater psychological or
cancer-speciﬁc distress, respectively. Secondary outcome measures were
the Functional Assessment of Cancer Therapy-Prostate29 and the Post-
traumatic Growth Inventory.30 Higher scores indicated a greater quality
of life or beneﬁt ﬁnding, respectively. Potential mediators of intervention
outcomes were mindfulness skills measured by the Five Facet Mind-
fulness Questionnaire.31 These include observing, describing, acting with
awareness, nonjudging of inner experience, and nonreactivity to inner
experience. Higher scores indicated greater engagement with that mind-
fulness skill.
Statistical Analyses
The target sample size was 190 men (95 in the MBCT intervention
group and 95 in the enhanced usual care group). By comparison with
simulations reported by Jo,32 this exceeded 80% power to detect an
effect of 0.75 (ie, a moderate to large effect) for two-sided comparisons
of continuous outcome means and allowed for 30% attrition from
treatment.
A series of random-effects, mixed-regression analyses examined
the effect of the MBCT intervention on changes in outcome variables
across the four assessment points. In each analysis, the intercept was
random. Where indicated by likelihood tests, the slope was also random
(ie, for the mindfulness skills of describing and nonjudging of inner
experience, only the intercept was random). Study condition and time
were entered as a product term to examine interaction effects on
outcome variables. Study condition (ie, enhanced usual care v MBCT
intervention) was captured as a dummy variable. Time in months was
a continuous predictor that was centered at baseline. All outcome
variables were summed as total scale scores. Main statistical analyses
were conducted on the basis of intention to treat. Toward this end,
all outcome analyses were conducted using direct maximal likeli-
hood estimation on the full data set, without dropping cases. Results are
reported as unstandardized regression weights (ie, b weights). Per-
protocol analyses were also conducted (four or more sessions attended
for the MBCT condition; Appendix Table A1, online only). Other re-
ported differences between study groups were assessed with t tests
for continuous variables or Pearson’s x2 for categorical variables.
Analyses were conducted using Stata software, Version 14 (Stata, College
Station, TX). Statistical tests were two-tailed, with a signiﬁcance level
of 5%.
RESULTS
Between September 2012 and January 2015, 472 men were referred
(Fig 1). Of these, 411 were eligible and 190 provided consent and
completed the baseline assessment. One man withdrew before
random assignment. The remaining 189 were randomly assigned
to enhanced usual care (n = 95) or to the MBCT intervention
(n = 94). There was no signiﬁcant difference in study withdrawal
between the enhanced usual care group (n = 6) and the MBCT
group (n = 13); x2(1) = 2.95, P = .086. Sociodemographic and
clinical characteristics of participants are reported in Table 1. There
were no signiﬁcant differences in sociodemographic or clinical
characteristics between the groups at baseline.
MBCTwas delivered by teleconference, with 14 participant
groups formed. A total of eight facilitators ran the groups. In
all, 49 men (52%) participated in four or more sessions (range,
zero to eight). The average length of a session was 85 minutes
(standard deviation, 12 minutes). Two groups were randomly
selected to assess facilitator adherence to MBCT delivery, and
the 16 session recordings were audited. The audited groups
had different facilitators. Interrater agreement was 95%. After
coding disagreement was resolved, the ﬁnal set of codes indicated
that facilitator adherence for each group was 97% and 93%,
respectively. Adherence ratings ranged from 83% to 100% for
group sessions.
Table 2 displays mean scores for primary and secondary
outcomes and mediator variables by study condition. No signiﬁcant
interactions between study condition and time were found for
psychological distress (b = 0.21, P = .117 [95% CI, 20.05 to
0.47]), cancer-speciﬁc distress (b = 20.13, P = .504 [95%
CI, 20.52 to 0.26]), prostate-speciﬁc antigen anxiety (b = 0.03,
P = .220 [95% CI, 20.02 to 0.09]), quality of life (b = 20.29,
P = .253 [95% CI, 20.79 to 0.21]), or beneﬁt ﬁnding (b = 0.24,
P = .411 [95% CI, 20.34 to 0.83]). For mindfulness skills, there
were no signiﬁcant interactions between study condition and
time for observing (b = 0.16, P = .089 [95% CI, 20.02 to 0.34]),
describing (b = 0.05, P = .488 [95% CI, 20.09 to 0.19]), acting
with awareness (b = 0.08, P = .318 [95% CI, 20.07 to 0.23]),
nonjudging of inner experience (b = 0.08, P = .282 [95% CI,20.07
to 0.24]), or nonreactivity to inner experience (b = 0.08, P = .431
[95% CI,20.12 to 0.28]). There were no signiﬁcant differences in
missing data between study groups for any outcomes across all
time points. Per-protocol analyses that were based on the 49 men
in the MBCT group who completed four or more sessions were
consistent with intention to treat and found no signiﬁcant in-
teractions between study condition and time on primary or
secondary outcomes. However, observing increased in these men
(b = 0.22, P = .032 [95% CI, 0.02 to 0.41]; Appendix Fig A1,
online only).
After the MBCT intervention, of the 61 men who completed
satisfaction surveys at 3 months, 72% rated the intervention as very
to extremely helpful. Aspects of the intervention reported as helpful
included the caring nature of the therapist, feeling not alone,
meditation and breathing exercises, understanding the meaning of
well-being, and control of thoughts and health. Barriers included
being physically unwell, ﬁnding it too time intensive, and wanting
more group discussion. At 6 and 9 months, 42 and 35 men in the
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Total referrals
(N = 472)
Potential participants
(n = 411)
Consented participants
(n = 190)
Baseline assessment
(n = 190)
Ineligible
(n = 61)
Study withdrawal
before
random assignment
(n = 1)
Randomly assigned
(n = 189)
Refused
(n = 221)
Allocated to enhanced usual care
(n = 95)
Study withdrawal      (n = 11)
Death          (n = 4)
Study withdrawal        (n = 1)
Death           (n = 2)
Study withdrawal         (n = 1)
Lost to follow-up           (n = 1)
Death             (n = 4)
Study withdrawal           (n = 4)
Lost to follow-up             (n = 1)
Study withdrawal          (n = 2)
Death                               (n = 5)
Intention-to-treat analysis
(n = 94)
Intention-to-treat analysis
(n = 95)
Three-month post–random
assignment SAQ
                  Completed
                Not completed
Six-month post–random
assignment SAQ
                  Completed
                Not completed
Nine-month post–random
assignment SAQ
                  Completed
                Not completed
Nine-month postintervention
SAQ 
       Completed         
       Not completed     
Six-month postintervention 
SAQ
                  Completed
                Not completed
Three-month postintervention SAQ
                  Completed
                Not completed
(n = 74)
(n = 69)
(n = 5)
(n = 79)
(n = 73)
(n = 6)
(n = 86)
(n = 77)
(n = 5)
(n = 95)
(n = 81)
(n = 5)
(n = 78)
(n = 68)
(n = 7)
(n = 79)
(n = 71)
(n = 7)
Allocated to MBCT intervention (n = 94)
(n = 26)
(n = 19)
(n = 21)
(n = 28)
(n = 27)Intervention withdrawal only
0 sessions
1 to 3 sessions
4 to 7 sessions
8 sessions
Fig 1. CONSORT ﬂow chart. MBCT, mindfulness-based cognitive therapy; SAQ, self-administered questionnaire.
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intervention (62% and 58%), respectively, had continued at least
occasional practice of mindfulness meditation in the past month
(less than once per week).
Only one adverse event was reported: in usual care at the
3-month follow-up, the educational resources were described as
distressing, and the participant withdrew.
Table 2. Scores for Enhanced Usual Care and MBCT Intervention Conditions Across Time Points
Variable
Baseline 3 Months 6 Months 9 Months
x ̅ SD x ̅ SD x ̅ SD x ̅ SD
Enhanced usual care*
Psychological distress† 10.52 10.24 10.11 10.31 9.90 9.92 9.44 8.97
Cancer-speciﬁc distress† 16.82 15.81 17.49 15.23 15.32 14.82 16.66 14.75
PSA anxiety† 1.16 1.79 0.91 1.44 0.91 1.57 0.86 1.44
Quality of life 110.03 20.39 110.18 20.12 110.16 20.82 110.22 20.67
Beneﬁt ﬁnding 57.92 21.91 55.40 21.55 58.76 20.92 59.71 21.72
Observing 23.06 6.74 24.00 7.90 23.83 7.45 24.62 7.32
Describing 29.07 6.80 29.35 6.60 29.08 6.61 29.38 6.58
Acting with awareness 31.40 6.04 31.23 6.48 31.29 6.44 30.40 6.50
Nonjudging of inner experience 32.32 6.78 32.15 7.36 33.05 6.91 32.11 6.93
Nonreactivity to inner experience 21.47 5.93 22.00 5.79 21.69 6.53 22.25 6.42
MBCT intervention‡
Psychological distress† 9.48 10.03 9.18 9.90 8.97 9.06 10.37 11.78
Cancer-speciﬁc distress† 14.62 15.33 13.04 11.54 12.18 12.53 13.00 14.31
PSA anxiety† 1.18 2.09 1.08 2.08 1.10 2.11 1.22 2.34
Quality of life 113.16 19.79 112.47 21.57 113.95 20.25 111.00 21.92
Beneﬁt ﬁnding 57.67 21.89 60.40 18.95 63.47 16.75 62.81 19.43
Observing 21.45 6.46 23.32 7.42 23.85 7.29 23.74 7.86
Describing 27.97 6.56 27.93 5.66 29.25 6.22 28.75 7.26
Acting with awareness 31.29 6.15 31.49 5.75 31.66 5.02 31.28 5.91
Nonjudging of inner experience 31.79 7.26 32.62 5.87 32.47 6.05 32.67 6.13
Nonreactivity to inner experience 19.98 5.61 20.64 5.69 21.40 6.45 20.95 6.28
NOTE. BSI-18 caseness indicates participants who met the criteria for clinically signiﬁcant distress according to Zabora et al.33
Abbreviations: MBCT, mindfulness-based cognitive therapy; PSA, prostate-speciﬁc antigen; SD, standard deviation.
*Baseline total = 95, BSI-18 caseness = 40 (42%); 3-month total = 81, BSI-18 caseness = 29 (36%); 6-month total = 77, BSI-18 caseness = 31 (40%); and 9-month total =
73, BSI-18 caseness = 26 (36%).
†Greater scores on primary outcomes indicate greater distress.
‡Baseline total = 94, BSI-18 caseness = 35 (37%); 3-month total = 71, BSI-18 caseness = 26 (37%); 6-month total = 68, BSI-18 caseness = 28 (41%); and 9-month total =
69, BSI-18 caseness = 26 (38%).
Table 1. Sociodemographic and Clinical Characteristics of Participants
Characteristic Enhanced Usual Care (n = 95) MBCT Intervention (n = 94)
Sociodemographic
Age, years, mean (SD) 71.18 (8.43) 70.19 (8.71)
Married 65 (68) 71 (76)
Children living at home 19 (21) 18 (19)
Born in Australia 58 (61) 68 (72)
British/Scottish/Welsh/Irish ethnic background 61 (49) 64 (51)
University or technical trade 65 (68) 60 (64)
Retired 65 (68) 64 (68)
Gross household income per year $ AUD$60,000 32 (36) 22 (24)
Disease*
Time since diagnosis, years, mean (SD) 6.58 (5.64) 5.25 (3.90)
PSA level, ng/mL, mean (SD) 60.03 (119.59) 40.89 (90.03)
Gleason score $ 8 at diagnosis 51 of 78 (65) 53 of 78 (68)
Treatment*
Androgen-deprivation therapy 86 of 87 (99) 79 of 83 (95)
Radiation therapy 63 of 87 (72) 55 of 83 (66)
Prostatectomy 34 of 87 (39) 41 of 83 (49)
Chemotherapy 29 of 86 (34) 24 of 83 (29)
Active surveillance 4 of 87 (5) 3 of 83 (4)
Watchful waiting 2 of 87 (2) 4 of 82 (5)
Orchidectomy 3 of 87 (3) 1 of 83 (1)
NOTE. Data are presented as No. (%) or n of N (%) unless indicated otherwise.
Abbreviations: MBCT, mindfulness-based cognitive therapy; PSA, prostate-speciﬁc antigen; SD, standard deviation.
*Data not available for all participants.
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DISCUSSION
In this randomized controlled trial, tele-based MBCT did not im-
prove psychological or quality-of-life outcomes in men with ad-
vanced PCwhen compared with those receiving minimally enhanced
usual care. In addition, MBCT did not inﬂuence mindfulness skills,
the proposed mechanisms of action for this therapeutic approach,
and despite men self-reporting MBCTas very helpful, these men did
not experience beneﬁts in psychological distress over time. On this
basis, at this time, we are not able to recommend tele-based group
MBCT as a psychological intervention for men with advanced PC.
This novel ﬁnding has important implications. Mindfulness-
based approaches have been taken up rapidly across multiple con-
texts despite limited evidence for efﬁcacy.34,35 However, it cannot be
assumed that any psychological intervention will necessarily be
helpful, and our ﬁnding underscores the dangers of naive realism
in clinical practice.36 Despite the men’s positive evaluations of the
experience, the intervention was not efﬁcacious and, moreover,
mindfulness skills did not change. It is plausible that in older
men, mindfulness skills are highly stable and difﬁcult to shift. We
previously reported cross-sectional data showing better psycho-
logical outcomes in men with advanced PC who were higher on all
mindfulness facets, with the exception of observing, where men
who were more able to observe and notice their experience had
greater distress.37 One might speculate that in the context of ad-
vancing disease, MBCT may shift the capacity to bear suffering,
rather than alleviate suffering per se. Speciﬁcally, increased
awareness of their illness, together with a commitment by men
to engage fully in life despite this, may have occurred. The role of
mindfulness in adjustment to cancer is an area in which future
longitudinal descriptive research is needed to further explore
adjustment mechanisms.
To date, mindfulness approaches in the cancer setting over-
represent women with breast cancer and seem helpful for that
population.38 Why might MBCT not have been effective in our
patients? Carlson et al39 have found mindfulness-based approaches
to be effective in reducing psychological morbidity in women with
breast cancer, with this effect more evident in per-protocol analyses
and in women who had a preference for mindfulness compared
with other options. The focus onmeditation and awareness, central
to mindfulness, may make this therapy more sensitive to individual
differences and motivations compared with standard cognitive
behavioral approaches. First, the mean age of women with breast
cancer in previous trials ranged from 45 to 61 years,38 younger than
themean age of 71 years in our cohort. Younger cancer populations
may be more receptive and responsive to mindfulness. Second, sex
may moderate treatment effect; where masculine preferences for
support and active coping styles are inﬂuential.40 Speciﬁcally, in
contrast to women with breast cancer, men with PC are less likely
to discuss their emotional concerns with their health care team,41
likely because of conﬂict between masculine attitudes and emo-
tional expression.42 Future research examining how masculinity
inﬂuences men’s adjustment to cancer and responses to support is
needed.43 Finally, we did not apply heightened distress as an in-
clusion criterion on the basis that these patients are well recognized
as being at risk of poorer psychological outcomes. However, across
time, only approximately 40% of our sample scored above standard
cutoff scores for signiﬁcant distress. Screening out low-distress
men may have enhanced the intervention effect.
Limitations in mindfulness intervention research to date in-
clude variable and low study quality.8-13 The strengths of our study
include adherence to CONSORT recommendations, intention-to-
treat analyses, assessment of treatment ﬁdelity, and examination of
mechanisms of effect. We do not have data on participant adherence
to home practice during the intervention, and participant therapy
adherence rates were lower than in some previous studies; however,
participation/recruitment and study retention rates were higher.44 A
limitation is that we did not include an attention control, but this
actually strengthens our ﬁnding that MBCT did not improve psy-
chological outcomes.
In conclusion, greater caution and rigorous evaluation are
needed before mindfulness-based approaches are applied across
multiple contexts. More research is needed to determine effective
ways of reducing psychological morbidity in men with advanced
PC, who remain a neglected group without proven interventions to
improve these outcomes.
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Appendix
Per-Protocol Analyses
For the per-protocol sample (four or more sessions attended), Table A1 displays mean scores for primary and secondary
outcomes and mediator variables by study condition. No signiﬁcant interactions were found between study condition and time on
psychological distress (b = 0.27, P = .078 [95% CI, 20.03 to 0.57]), cancer-speciﬁc distress (b = 0.05, P = .824 [95% CI,20.39 to
0.49]), PSA anxiety (b = 0.02, P = .382 [95% CI,20.03 to 0.08]), quality of life (b =20.27, P = .360 [95% CI,20.86 to 0.31]), or
beneﬁt ﬁnding (b = 0.18, P = .567 [95% CI, 20.44 to 0.81]).
Regarding mindfulness skills, there was a signiﬁcant interaction between study condition and time on observing (b = 0.22,
P = .032 [95% CI, 0.02 to 0.41]). The predicted observing values increased from baseline to 9-month follow-up in the MBCT
condition (Fig A1). The effect size was small (Cohen’s d = 0.13). The predicted trajectory appeared ﬂat for enhanced usual care. No
signiﬁcant interactions were found between study condition and time on describing (b = 0.10, P = .221 [95% CI,20.06 to 0.25]),
acting with awareness (b = 0.09, P = .316 [95% CI,20.08 to 0.26]), nonjudging of inner experience (b = 0.12, P = .173 [95% CI,20.05
to 0.30]), or nonreactivity to inner experience (b = 0.16, P = .147 [95% CI, 20.06 to 0.38]).
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Fig A1. Predicted observing trajectory by study condition in per-protocol anal-
ysis. Error bars show 95% CI.
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Table A1. Mean Scores for Enhanced Usual Care and MBCT Intervention (per protocol) Conditions
Variable
Baseline 3 Months 6 Months 9 Months
x ̅ SD x ̅ SD x ̅ SD x ̅ SD
Enhanced usual care*
Psychological distress† 10.52 10.24 10.11 10.31 9.90 9.92 9.44 8.97
Cancer-speciﬁc distress† 16.82 15.81 17.49 15.23 15.32 14.82 16.66 14.75
PSA anxiety† 1.16 1.79 0.91 1.44 0.91 1.57 0.86 1.44
Quality of life 110.03 20.39 110.18 20.12 110.16 20.82 110.22 20.67
Beneﬁt ﬁnding 57.92 21.91 55.40 21.55 58.76 20.92 59.71 21.72
Observing 23.06 6.74 24.00 7.90 23.83 7.45 24.62 7.32
Describing 29.07 6.80 29.35 6.60 29.08 6.61 29.38 6.58
Acting with awareness 31.40 6.04 31.23 6.48 31.29 6.44 30.40 6.50
Nonjudging of inner experience 32.32 6.78 32.15 7.36 33.05 6.91 32.11 6.93
Nonreactivity to inner experience 21.47 5.93 22.00 5.79 21.69 6.53 22.25 6.42
MBCT intervention (per protocol)‡
Psychological distress† 9.14 9.65 9.88 10.80 9.54 9.68 11.72 13.12
Cancer-speciﬁc distress† 14.78 15.23 12.90 11.80 13.21 13.46 14.83 15.53
PSA anxiety† 1.32 2.09 1.06 2.13 1.04 2.03 1.30 2.52
Quality of life 113.80 19.27 113.22 20.68 113.55 20.98 109.47 23.94
Beneﬁt ﬁnding 60.00 22.12 61.15 18.51 62.65 17.29 63.47 18.36
Observing 22.51 7.53 25.00 7.34 25.19 7.24 25.51 7.88
Describing 28.95 6.37 28.48 6.08 29.78 6.04 29.66 7.47
Acting with awareness 30.80 6.29 30.65 5.80 31.48 5.01 30.64 5.94
Nonjudging of inner experience 31.00 8.04 32.33 5.99 32.06 6.47 32.17 6.57
Nonreactivity to inner experience 20.73 5.64 21.75 5.94 22.67 6.10 22.26 5.87
Abbreviations: MBCT, mindfulness-based cognitive therapy; PSA, prostate-speciﬁc antigen; SD, standard deviation.
*Baseline (n = 95); 3 months (n = 81); 6 months (n = 77); and 9 months (n = 73).
†Greater scores on primary outcomes indicate greater distress.
‡Baseline (n = 49); 3 months (n = 48); 6 months (n = 46); and 9 months (n = 47).
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